Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, 02-776 Warsaw, Poland.
Vet Rec. 2009 Nov 28;165(22):657-60. doi: 10.1136/vr.165.22.657.
Fourteen female cats with fibroadenomatosis were treated with aglepristone, and the effectiveness of the treatment and its effect on selected haematological and blood chemistry parameters were studied. The cats were monitored for 12 months after the end of the treatment. Complete remission of the clinical signs was achieved on average 3.9 weeks after the treatment began; the success of the treatment confirmed the clinical diagnosis of fibroadenomatosis. During the course of the treatment the cats' haematological parameters returned to normal. In cats that had previously been treated with long-acting medroxyprogesterone acetate, treatment with aglepristone for five weeks was recommended. Cases of fibroadenomatosis reappearing after a few months should be regarded as new disease rather than a relapse. Six cats were subsequently mated and four gave birth to one or more litters; all the pregnancies proceeded normally with no clinically evident fibroadenomatosis. The other eight cats underwent ovariohysterectomy soon after the aglepristone treatment was completed.
14 只患有纤维腺瘤病的雌性猫接受了阿格来司琼治疗，并研究了治疗效果及其对选定的血液学和血液化学参数的影响。治疗结束后，这些猫被监测了 12 个月。平均在治疗开始后 3.9 周，临床症状完全缓解；治疗的成功证实了纤维腺瘤病的临床诊断。在治疗过程中，猫的血液学参数恢复正常。对于以前接受过长效甲孕酮治疗的猫，建议使用阿格来司琼治疗 5 周。几个月后纤维腺瘤病再次出现的病例应视为新疾病而不是复发。随后有 6 只猫交配，其中 4 只生了一窝或多窝；所有怀孕都正常进行，没有明显的纤维腺瘤病。其余 8 只猫在阿格来司琼治疗完成后不久接受了卵巢子宫切除术。
